Abbott Labs Deserves Its Premium – Analyst Blog
Source: http://www.zacks.com/stock/news/16512/Abbott+Labs+Deserves+Its+Premium+-+Analyst+BlogPosted on Monday, December 22nd, 2008 | In Stocks to Watch
Abbott Laboratories (ABT) discovers, develops, manufactures and sells a diversified line of healthcare products. We expect double-digit EPS growth over the next few years driven by strong sales of Humira and the company’s rapidly growing vascular business.
Several new drug applications have recently been filed with the FDA which should accelerate sales in the pharmaceutical business. Based on our model, the company is expected to deliver high single-digit EPS growth through the end of 2013.
We believe ABT possesses a low-risk profile and will continue to trade at an industry premium. Accordingly, we reiterate our Buy recommendation with a price target of $65.
Jason Napodano, CFA contributed to this report.
Read the full analyst report on ABT
“ABT” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Company News for November 25, 2009 - Corporate Summary - November 25th, 2009
- Stock Market News for November 25, 2009 - Market News - November 25th, 2009
- Manulife Buys Stake, Raises Equity - Analyst Blog - November 25th, 2009
- NCR Rolls Out New Products - Analyst Blog - November 25th, 2009
- Zacks Bull and Bear of the Day Highlights: MEMC Electronic Materials, Inc., Energy Transfer Partners, Ford, Whirlpool and Wal-Mart - Press Releases - November 25th, 2009
Abbott Laboratories, Abbott Labs, Blog, Fda, healthcare products, Humira, Jason Napodano, Pharmaceutical, Stocks to Watch, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.